Literature DB >> 23224447

The role of psychotic disorders in religious history considered.

Evan D Murray1, Miles G Cunningham, Bruce H Price.   

Abstract

The authors have analyzed the religious figures Abraham, Moses, Jesus, and St. Paul from a behavioral, neurologic, and neuropsychiatric perspective to determine whether new insights can be achieved about the nature of their revelations. Analysis reveals that these individuals had experiences that resemble those now defined as psychotic symptoms, suggesting that their experiences may have been manifestations of primary or mood disorder-associated psychotic disorders. The rationale for this proposal is discussed in each case with a differential diagnosis. Limitations inherent to a retrospective diagnostic examination are assessed. Social models of psychopathology and group dynamics are proposed as explanations for how followers were attracted and new belief systems emerged and were perpetuated. The authors suggest a new DSM diagnostic subcategory as a way to distinguish this type of psychiatric presentation. These findings support the possibility that persons with primary and mood disorder-associated psychotic symptoms have had a monumental influence on the shaping of Western civilization. It is hoped that these findings will translate into increased compassion and understanding for persons living with mental illness.

Entities:  

Mesh:

Year:  2012        PMID: 23224447     DOI: 10.1176/appi.neuropsych.11090214

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  3 in total

1.  Christianity and Schizophrenia Redux: An Empirical Study.

Authors:  Szabolcs Kéri; Oguz Kelemen
Journal:  J Relig Health       Date:  2020-02

2.  Spirituality, dimensional autism, and schizotypal traits: The search for meaning.

Authors:  Bernard Crespi; Natalie Dinsdale; Silven Read; Peter Hurd
Journal:  PLoS One       Date:  2019-03-08       Impact factor: 3.240

Review 3.  Pivotal mental states.

Authors:  Ari Brouwer; Robin Lester Carhart-Harris
Journal:  J Psychopharmacol       Date:  2020-11-11       Impact factor: 4.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.